Skip To Main Content
Rajappa S. Kenchappa on Muck Rack

Rajappa S. Kenchappa

As seen in: BioRxiv, Cell Reports
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rajappa S.

Contact Rajappa S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

MT-125 Inhibits Non-Muscle Myosin IIA and IIB, Synergizes with Oncogenic Kinase Inhibitors, and Prolongs Survival in Glioblastoma

|
By Rajappa S. Kenchappa, László Radnai, Erica Young, Natanael Zarco
| BioRxiv
Abstract We have identified a NMIIA and IIB-specific small molecule inhibitor, MT-125, and have studied its effects in GBM. MT-125 has high brain penetrance and retention and an excellent safety profile; blocks GBM invasion and cytokinesis, consistent with the known roles of NMII; and prolongs survival as a single agent in murine GBM models.
Open in Who Shared Issue with article?

Protein kinase Cι and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities

|
By Yi Liu, Michael G Argenziano, Rajappa S. Kenchappa
| Cell Reports Verified
Highlights • PKCι is an oncogenic driver of GBM that confers response to PKCι inhibitor therapy • GBMs can be classified into mutually exclusive PKCι- or SRC-dependent subtypes • PKCι- and SRC-dependent cells often co-exist in single GBM tumors • Combined PKCι and SRC inhibition is an effective treatment strategy for GBM Summary We report that atypical protein kinase Cι (PKCι) is an oncogenic driver of glioblastoma (GBM).
Open in Who Shared Issue with article?
See all 2 articles